Ardent Healthcare Partners Inc. (ARDT-N)
NYSE:ARDT
12.58
0.28
(2.28%) 1d
Financials
Technical Analysis
Buy, Sell or Hold?
Related posts
Nervous markets await Nvidia
- «
- ‹
- 1
- ›
- »
Ardent Healthcare Partners Inc.(ARDT-N) Rating
Ranking : 1 out of 5
Bullish - Buy Signals / Votes : 0
Neutral - Hold Signals / Votes : 0
Bearish - Sell Signals / Votes : 0
Total Signals / Votes : 0
Ardent Healthcare Partners Inc.(ARDT-N) Frequently Asked Questions
What is Ardent Healthcare Partners Inc. stock symbol?
Ardent Healthcare Partners Inc. is a American stock, trading under the symbol ARDT-N on the New York Stock Exchange (ARDT). It is usually referred to as NYSE:ARDT or ARDT-N
Is Ardent Healthcare Partners Inc. a buy or a sell?
In the last year, there was no coverage of Ardent Healthcare Partners Inc. published on Stockchase.
Is Ardent Healthcare Partners Inc. a good investment or a top pick?
Ardent Healthcare Partners Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Ardent Healthcare Partners Inc..
Why is Ardent Healthcare Partners Inc. stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Ardent Healthcare Partners Inc. worth watching?
In the last year 0 stock analysts on Stockchase covered Ardent Healthcare Partners Inc.. The stock is worth watching.
What is Ardent Healthcare Partners Inc. stock price?
On 2025-04-24, Ardent Healthcare Partners Inc. (ARDT-N) stock closed at a price of $12.58.
This operator of 30 acute care hospitals and 200 care sites in the US is a TOP PICK. They are managing through turbulent times for the sector, while growing cash reserves and reducing debt. Nursing costs are stabile and they will soon know about a partnership in New Mexico which analysts believe will further stimulate cash flow. It trades at 9x earnings, 1.6x book and supports a 23% ROE. We recommend setting a stop-loss at $8.00, looking to achieve $16.50 -- upside potential of 28%. Yield 0%
(Analysts’ price target is $19.90)